Skip to main content
SpringerLink
Log in

Effectiveness and safety of orelabrutinib with rituximab and lenalidomide in low KPS score and elderly patients with newly diagnosed primary central nervous system lymphoma—a single-center retrospective study

  • Letter to the Editor
  • Published:
Neurological Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Soussain C, Malaise D, Cassoux N (2021) Primary vitreoretinal lymphoma: a diagnostic and management challenge. Blood 138(17):1519–1534

    Article  CAS  PubMed  Google Scholar 

  2. Radke J, Ishaque N, Koll R, Gu Z, Schumann E, Sieverling L et al (2022) The genomic and transcriptional landscape of primary central nervous system lymphoma. Nat Commun 13(1):2558

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D et al (2017) Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov 7(9):1018–1029

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Houillier C, Chabrot CM, Moles-Moreau MP, Willems L, Ahle G, Waultier-Rascalou A et al (2021) Rituximab-lenalidomide-ibrutinib combination for relapsed/refractory primary CNS lymphoma: a case series of the LOC Network. Neurology 97(13):628–631

    Article  CAS  PubMed  Google Scholar 

  5. Dhillon S (2021) Orelabrutinib: first approval. Drugs 81(4):503–507

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This work was supported by the National Natural Science Foundation of Hebei Province (H2020206438).

Author information

Authors and Affiliations

  1. Department of Hematology, The Second Hospital of Hebei Medical University, No. 215, Heping West Road, Shijiazhuang, 050000, Hebei, China

    Xiao-Ling Guo, Zi-Yu Zhao, Xue-Fei Guo, Ya-Bei Zuo, Jin-Ao Li, Zi-Yuan Nie & Jin-Hai Ren

Authors
  1. Xiao-Ling Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zi-Yu Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xue-Fei Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ya-Bei Zuo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jin-Ao Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zi-Yuan Nie
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jin-Hai Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Zi-Yuan Nie or Jin-Hai Ren.

Ethics declarations

Ethical approval and consent to participate

All the protocols of this study were approved by the Ethics Committee of 2nd Hospital of Hebei Medical University.

Consent for publication

Written consent was obtained from all participants.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guo, XL., Zhao, ZY., Guo, XF. et al. Effectiveness and safety of orelabrutinib with rituximab and lenalidomide in low KPS score and elderly patients with newly diagnosed primary central nervous system lymphoma—a single-center retrospective study. Neurol Sci 45, 2931–2934 (2024). https://doi.org/10.1007/s10072-024-07348-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-024-07348-4

Search

Navigation